At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Serelaxin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease
In Brief
A Phase 2 clinical trial evaluating Serelaxin and Placebo for Coronary Artery Disease. Completed, enrolled 58 participants across 3 sites.
Detailed Summary
This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartFeb 2014
Primary CompletionAug 2016
TodayJul 2026
First PostedNov 8, 2013
Enrollment StartFeb 3, 2014
Primary CompletionAug 17, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.7 years ago
Interventions
Serelaxindrug
Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
Placeboother
5% v/v glucose solution